Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast

$DH
Computer Software: Prepackaged Software
Technology
Get the next $DH alert in real time by email

FRAMINGHAM, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/.

A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly after the conclusion of the call, a replay of this conference call will be available through March 29, 2025 at 800-645-7964 or 757-849-6722. The replay passcode is 1765#.

About Definitive Healthcare

At Definitive Healthcare, our mission is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow's healthcare industry. Our SaaS products and solutions create new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

Media Contact:

Bethany Swackhamer

bswackhamer@definitivehc.com

Investor Relations Contact:

Brian Denyeau

ICR for Definitive Healthcare

brian.denyeau@icrinc.com

Source: Definitive Healthcare Corp.



Primary Logo

Get the next $DH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DH

DatePrice TargetRatingAnalyst
1/13/2025$4.00Equal Weight → Underweight
Barclays
12/20/2024$5.00Equal-Weight
Stephens
9/17/2024$7.00Buy
BTIG Research
7/31/2024$7.00 → $5.00Neutral → Underweight
JP Morgan
5/8/2024$11.50 → $9.00Overweight → Equal-Weight
Morgan Stanley
1/17/2024Buy → Hold
Needham
1/5/2024Buy → Hold
Canaccord Genuity
7/24/2023$13.00Outperform → Neutral
Robert W. Baird
More analyst ratings

$DH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

    FRAMINGHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of one senior leader, the Human Capital Management and Compensation Committee (the "Committee") of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Jeff Moyer, Definitive Healthcare's new SVP of Growth and Sales Operations, an inducement award consisting of 364,432 time-based restricted stock units ("RSUs"), effective April 3, 2025. These awards were individually negotiated and granted as an inducement material to Mr. Moyer's respective commencement of

    $DH
    Computer Software: Prepackaged Software
    Technology
  • Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

    FRAMINGHAM, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of two senior leaders, the Human Capital Management and Compensation Committee (the "Committee") of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Kate Hastings, Definitive Healthcare's new Chief Customer Officer an inducement award consisting of 172,414 time-based restricted stock units ("RSUs") effective March 3, 2025 and granted Benjamin Graboske, Definitive Healthcare's new EVP, Technology, Engineering and Chief Data Officer an inducement award co

    $DH
    Computer Software: Prepackaged Software
    Technology
  • Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024

    FRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Financial Highlights: Revenue was $62.3 million, a decrease of 6% from $65.9 million in Q4 2023. Net Loss, inclusive of goodwill impairment charges of $97.1 million, was $(84.7) million, or (136)% of revenue, compared to $(13.4) million or (20)% of revenue in Q4 2023.  Adjusted Net Income was $12.6 million, compared to $10.6 million in Q4 2023.   Adjusted EBITDA was $17.5 million, or 28%

    $DH
    Computer Software: Prepackaged Software
    Technology

$DH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$DH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$DH
SEC Filings

See more

$DH
Leadership Updates

Live Leadership Updates

See more
  • Definitive Healthcare Appoints Kevin Coop as CEO for Next Phase of Company's Growth

    FRAMINGHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Kevin Coop as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition. "Kevin is an outstanding leader. He has deep, hands-on experience with data-focused businesses and has a

    $DH
    Computer Software: Prepackaged Software
    Technology
  • Established Executive and Milwaukee Business Leader Jim Emling Joins VBA as Executive Chair of the Board of Directors

    Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv

    $DH
    $GDRX
    Computer Software: Prepackaged Software
    Technology
    EDP Services
  • Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer

    FRAMINGHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023. "I am thrilled to welcome Carrie Lazorchak to Definitive Healthcare as our new Chief Revenue Officer," said Robert Musslewhite, Chief Executive Officer of Definitive Healthcare. "Carrie is a fantastic fit for Definitive Healthcare. Her values and her deep belief in the power of humble collaboration make her a perfect match for our culture. Carrie brings a wealth of experience selling Software as a Service to both enterprise accounts and

    $DH
    Computer Software: Prepackaged Software
    Technology

$DH
Financials

Live finance-specific insights

See more
  • Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024

    FRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Financial Highlights: Revenue was $62.3 million, a decrease of 6% from $65.9 million in Q4 2023. Net Loss, inclusive of goodwill impairment charges of $97.1 million, was $(84.7) million, or (136)% of revenue, compared to $(13.4) million or (20)% of revenue in Q4 2023.  Adjusted Net Income was $12.6 million, compared to $10.6 million in Q4 2023.   Adjusted EBITDA was $17.5 million, or 28%

    $DH
    Computer Software: Prepackaged Software
    Technology
  • Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast

    FRAMINGHAM, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (i

    $DH
    Computer Software: Prepackaged Software
    Technology
  • Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2024

    FRAMINGHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2024.  Third Quarter 2024 Financial Highlights: Revenue was $62.7 million, a decrease of 4% from $65.3 million in Q3 2023. Net Loss, inclusive of goodwill impairment charges of $228.2 million, was $(187.8) million, or (300%) of revenue, down 24% compared to $(248.7) million, inclusive of goodwill impairment charges of $287.4 million, or (381%) of revenue in Q3 2023.Adjusted Ne

    $DH
    Computer Software: Prepackaged Software
    Technology

$DH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more